General electrophilic small molecules

General electrophilic small molecules represent a broad class of chemical entities characterized by their ability to accept electron pairs from nucleophilic centers, such as the thiol groups of cysteine or the amino groups of lysine residues on proteins. In modern pharmacology, these molecules are frequently designed as targeted covalent inhibitors (TCIs) to form permanent chemical bonds with specific protein targets, providing high potency and a prolonged duration of action (Source: Nature Reviews Drug Discovery 2011, 10, 307–317). While this chemical modality is used to treat various conditions, including cancer and autoimmune diseases, the term itself refers to a chemical reactivity profile rather than a specific biological receptor or enzyme. The primary biological impact of these molecules involves the irreversible modification of protein function, which can be leveraged for therapeutic benefit or, conversely, lead to toxicological outcomes. Safety is a critical consideration, as non-specific electrophilic reactivity can result in off-target protein binding, leading to idiosyncratic drug-induced liver injury or immune-mediated hypersensitivity (Source: Chemical Research in Toxicology 2013, 26, 8, 1129–1139). Consequently, drug development focuses on 'tuned' electrophiles that balance reactivity with high selectivity for the intended biological target.

Other names

ElectrophilesCovalent modifiersReactive electrophilic speciesTargeted covalent inhibitorsElectrophilic warheads

Formation of a stable covalent bond with nucleophilic amino acid side chains (typically Cysteine, Lysine, Histidine, or Tyrosine) through chemical reactions such as Michael addition, nucleophilic substitution (SN2), or acylation (Source: Journal of Medicinal Chemistry 2016, 59, 11, 5142–5156).